Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Liabilities and Shareholders Equity (2023 - 2025)

Bioharvest Sciences has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $47.7 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 90.65% year-over-year to $47.7 million; the TTM value through Dec 2025 reached $137.2 million, up 33.45%, while the annual FY2025 figure was $47.7 million, 90.65% up from the prior year.
  • Liabilities and Shareholders Equity was $47.7 million for Q4 2025 at Bioharvest Sciences, up from $35.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $47.7 million in Q4 2025 and bottomed at $15.0 million in Q4 2023.
  • The 3-year median for Liabilities and Shareholders Equity is $26.6 million (2025), against an average of $28.3 million.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 90.65% in 2025, down 2.9% in 2025.
  • Over 3 years, Liabilities and Shareholders Equity stood at $15.0 million in 2023, then skyrocketed by 66.65% to $25.0 million in 2024, then surged by 90.65% to $47.7 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $47.7 million (Q4 2025), $35.2 million (Q3 2025), and $27.8 million (Q2 2025) per Business Quant data.